We're taking a closer look at Arcturus Therapeutics today, as the chatter surrounding the stock has increased notably in the last few weeks. Today, its shares moved 26.4% compared to 1.0% for the S&P 500. Increased investor interest and volatility surrounding the stock are not reason enough to buy in -- you should first perform your own due diligence. Here are some figures that can get you started:
-
Arcturus Therapeutics Holdings Inc. operates as a late-stage clinical mRNA medicines and vaccines company.
-
Arcturus Therapeutics has moved -43.7% over the last year
-
ARCT has an average analyst rating of hold and is -50.82% away from its mean target price of $39.83 per share
-
Its trailing 12 month earnings per share (EPS) is $-5.44
-
Arcturus Therapeutics has a trailing 12 month Price to Earnings (P/E) ratio of -3.6 while the S&P 500 average is 15.97
-
Its forward earnings per share (EPS) is $-3.04 and its forward P/E ratio is -6.4
-
The company has a Price to Book (P/B) ratio of 3.6 in contrast to the S&P 500's average ratio of 2.95
-
Arcturus Therapeutics is part of the Health Care sector, which has an average P/E ratio of 24.45 and an average P/B of 4.16
-
Arcturus Therapeutics has on average reported free cash flows of $-63,438,333.30 over the last four years, during which time they have grown by an an average of -241.5%